Full-Time

Field Medical Senior Manager

MD

Posted on 5/9/2026

Deadline 5/20/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

No salary listed

No H1B Sponsorship

Iowa, USA + 4 more

More locations: Minnesota, USA | Wisconsin, USA | Indiana, USA | Illinois, USA

Hybrid

Travel up to 50-80%; reside in MN, WI, IA, IL, IN.

Category
Biology & Biotech (1)
Required Skills
Data Analysis
Requirements
  • MD degree required
  • 0+ years of relevant experience in clinical practice, clinical research, health services research, or pharmaceutical/biotechnology medical affairs, demonstrating increasing levels of responsibility, judgment, and autonomy consistent with a Senior Manager individual contributor role
  • Experience engaging healthcare professionals in independent scientific exchange and medical decision‑making required
  • Demonstrated clinical and technical expertise applicable to scientific exchange and medical engagement
  • Excellent oral, written, and presentation communication skills
  • Strong interpersonal skills with the ability to engage, influence, and collaborate effectively with diverse internal and external stakeholders
  • Ability to manage multiple priorities in a remote, field‑based environment while exercising sound judgment and accountability
  • Comfort operating within a matrixed organization and contributing to cross‑functional initiatives
  • Demonstrated change agility and adaptability within a dynamic healthcare and organizational environment
  • Strong problem‑solving skills and ability to network enterprise‑wide to identify solutions
  • Proficiency in using digital technologies and platforms to support medical engagement and documentation
  • Demonstrated ability to synthesize scientific evidence, real‑world insights, and customer perspectives to inform medical strategy and advance discussions focused on improving care and patient outcomes
Responsibilities
  • Plan and execute medical strategy and engagement with appropriately identified customers within an assigned territory, coordinating compliantly with cross‑functional Pfizer colleagues to achieve medical objectives
  • Maintain a high level of scientific and therapeutic area knowledge, including disease states, standards of care, emerging data, and Pfizer medicines, to support meaningful scientific exchange
  • Deliver truthful, balanced, accurate, and scientifically supported information in response to unsolicited medical requests from HCPs, in compliance with all applicable Pfizer policies, SOPs, and regulatory requirements
  • Serve as a conduit for medical information and customer insights, sharing externally derived insights with internal partners to inform medical strategy, content development, and execution.
  • Identify and explore areas where real‑world clinical practice, systems of care, or patient experience may diverge from established evidence, guidelines, or evolving scientific understanding, and engage customers in scientific dialogue to better understand contributing factors and potential opportunities for improvement
  • Maintain effective communication and collaboration with headquarters Medical Affairs colleagues, Medical Information, and Field Medical peers to ensure alignment with medical priorities
  • Demonstrate strong communication skills across multiple channels, including live and virtual presentations, written scientific communication, and one‑to‑one or group discussions
  • Optimize patient centricity in medical communications and engagements, incorporating health literacy and cultural awareness principles so that patients remain the ultimate focus
  • Support patient‑focused discussions that highlight unmet needs, variability in care delivery, and barriers to optimal outcomes across diverse care settings, ensuring engagements remain grounded in scientific evidence and compliant medical exchange
  • Deliver approved medical content related to Pfizer medicines and relevant disease‑state topics to HCPs across a variety of settings, including local, regional, and national forums
  • Identify, prioritize, and engage appropriate customer segments within the assigned therapeutic area, including individual HCPs and organized customers such as medical groups, integrated delivery networks, payers, and other decision‑making bodies, as appropriate
  • Field and manage inbound medical inquiries through established Pfizer triage processes and ensure timely, compliant follow‑up
  • Partner with Global Medical Affairs, Worldwide Research & Development, and Global Product Development to support identification and engagement of appropriate sites and investigators for Pfizer‑sponsored clinical trials, including those serving under‑represented patient populations
  • Provide medical support throughout the Investigator Sponsored Research (ISR) lifecycle in accordance with Pfizer guidance, including investigator engagement and scientific exchange.
  • Cultivate research and therapeutic area expertise by reviewing scientific literature, monitoring competitive landscapes, attending scientific congresses, and engaging with external experts
  • Understand and communicate principles of clinical study design, methodology, data analysis, and interpretation during scientific discussions with customers
  • Reactively and proactively engage, as appropriate, with local patient advocacy organizations in collaboration with Corporate Affairs and headquarters Medical Affairs
  • Deliver insights regarding local patient organization structures, capabilities, and unmet patient needs to inform medical strategy and planning
  • Serve on therapeutic area, asset, and cross‑functional committees or initiatives, contributing medical expertise and insights
  • Partner with internal Medical Affairs colleagues, analytics teams, and cross‑functional stakeholders to support the prioritization, alignment, and evolution of medical initiatives informed by observed patterns, trends, and opportunities to improve care delivery
  • Represent Pfizer Medical Affairs with professionalism in interactions with clinical, scientific, and professional associations and societies
  • Maintain timely completion of all internal training requirements and compliance expectations
  • Appropriately utilize digital tools and platforms to engage customers and document medical interactions in accordance with Pfizer systems and policies
Desired Qualifications
  • Prior Field Medical or Medical Affairs experience
  • Familiarity with internal and external regulations, codes, and guidelines governing pharmaceutical industry interactions with healthcare professionals

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer medicines grew 22% operationally in Q1 2026, offsetting COVID product declines.
  • VYNDAMAX patent extension to 2031 stabilizes 75% market share cardiology revenue.
  • ELREXFIO Phase 3 data positions multiple myeloma drug against J&J, BMS competitors.

What critics are saying

  • Eliquis patent expiration 2026-2027 eliminates $1.5B revenue via generic competition.
  • Ibrance patent cliff 2027 erodes $5B+ annual oncology revenue with no successor.
  • COVID product sales collapsed from $56.7B 2022 to $5B projected 2026.

What makes Pfizer unique

  • Seagen acquisition doubled oncology pipeline to 60 programs with proprietary ADC technology.
  • VEPPANU first FDA-approved oral PROTAC therapy for endocrine-resistant breast cancer.
  • HYMPAVZI EU approval targets 20% hemophilia A patients with inhibitors, 93% bleeding reduction.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Pfizer who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.